Menu

Thermo Fisher Scientific Inc. TMO

Full chart Compare
Set alert

Price alert · TMO

All alert types
676.94 USD -29.22 (-4.14%)

At closeNov 5, 2026, 6:32 PM EST

673.86 -3.08 -0.45%

After hours · Nov 5, 6:32 PM ET

676.13 Day range 708.93
435.27 52-week range 712.17
YTD
+16.82%
1 year
+19.26%
Market cap
250.82B
Revenue (ttm)
47.35B
Profit margin
14.94%
EPS (ttm)
18.18
Shares out
370.52M
P/E ratio
37.24
Forward P/E
25.41
Dividend
1.88 (0.27%)
Ex-dividend date
Sep 14, 2026
YTD return
+16.82%
1-year return
+19.26%
Volume
2.83M
Avg volume
2.10M
Open
706.92
Previous close
706.16
Day's range
676.13 – 708.93
52-week range
435.27 – 712.17
Beta
0.84
Analysts
Strong Buy
Price target
752.12 (+11.1%)
Earnings date
Feb 4, 2027

5D -25.97 (-3.69%)

680690700710FriMonTueWedThu676.94

Key statistics

Enterprise value
294.19B
PEG ratio
2.02
Price / sales
5.52
Price / book
4.78
Dividend yield
0.27%
Payout ratio
9.70%
Revenue growth
9.10%
Free cash flow
6.44B
Total cash
6.06B
Total debt
41.37B
Return on equity
13.38%
Short % of float
1.32%
50-day average
657.11
200-day average
552.06

Financials — quick view

All financials
TMO Revenue — quarterly 12.14B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
TMO Net income — quarterly 1.72B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
TMO EPS — quarterly 4.65
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

TMO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 4, 2027Dec 26, 20267.13———
Oct 21, 2026Sep 26, 20266.406.68+0.28+4.37%
Jul 23, 2026Jun 27, 20265.726.03+0.31+5.42%
Apr 23, 2026Mar 28, 20265.255.44+0.19+3.62%
Jan 29, 2026Dec 31, 20256.456.57+0.12+1.86%
Oct 22, 2025Sep 27, 20255.505.79+0.29+5.27%

Upgrades / downgrades

TMO analyst upgrades and downgrades
DateFirmActionFromTo
Oct 30, 2026Argus ResearchmainBuyBuy
Oct 23, 2026CitigroupmainBuyBuy
Oct 22, 2026BarclaysmainOverweightOverweight
Oct 22, 2026RBC CapitalmainSector PerformSector Perform
Oct 22, 2026TD CowenmainBuyBuy
Oct 22, 2026StifelmainBuyBuy

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States

News

Your note

Sign in to keep a note on TMO — it syncs with the Stock Master app.

Insider holders

TMO insider holders
InsiderRelationLatest transactionDateShares held
BOXER MICHAEL AGeneral CounselSaleMar 9, 202510,815
BRITT LISA POfficerSaleAug 18, 202614,784
CASPER MARC NChief Executive OfficerSaleAug 23, 2026140,225
CHAI NELSON JDirectorStock Award(Grant)May 19, 202615,316
LAGARDE MICHELChief Operating OfficerStock Award(Grant)Feb 24, 202686,347
LOWERY FREDERICK M.OfficerStock Award(Grant)Feb 24, 202617,133

Institution ownership

TMO institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.35%30,919,63221.83BJun 29, 2026
Vanguard Capital Management LLC6.55%24,276,31617.14BJun 29, 2026
State Street Corporation4.54%16,825,87911.88BJun 29, 2026
FMR, LLC3.80%14,084,4889.94BJun 29, 2026
Morgan Stanley2.90%10,763,0667.60BJun 29, 2026
JPMORGAN CHASE & CO2.30%8,503,5276.00BJun 29, 2026

Fund ownership

TMO fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%11,797,8008.33BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.60%9,628,7136.80BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%4,926,5073.48BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%4,805,2163.39BSep 29, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.23%4,572,5553.23BSep 29, 2026
Fidelity Contrafund1.11%4,123,9662.91BAug 30, 2026